BGNE
BeiGene Ltd
Halal Rating :
Last Price
$210.14
Last updated:
Market Cap
-
7D Change
13.83%
1 Year Change
34.17%
Company Overview
Industries
Exchange
Next Earnings Date
BeiGene is a global biotechnology company focused on developing innovative and affordable medicines to treat cancer. The company develops, manufactures, and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene has a broad portfolio of oncology drugs and candidates in development, with operations in China, the United States, Europe, and Australia.
Use of Interest
Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $1.0b | $1.12b | - | - | 0.00% | 0.00% |
June 30, 2024 | $929.17m | $1.02b | - | $-13225000.0 | 0.00% | 1.29% |
March 31, 2024 | $751.65m | $996.84m | - | $-16160000.0 | 0.00% | 1.62% |
Company Impact
Help us evaluate BeiGene Ltd's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.